Precigen, Inc.
(NASDAQ : PGEN)

( )
PGEN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.48%246.731.5%$893.73m
MRNAModerna, Inc. 3.73%155.540.0%$852.62m
VRTXVertex Pharmaceuticals, Inc. 0.58%288.981.9%$508.85m
GILDGilead Sciences, Inc. -0.03%62.341.0%$477.30m
NVAXNovavax, Inc. 12.49%64.2975.7%$468.89m
REGNRegeneron Pharmaceuticals, Inc. 0.20%596.562.6%$452.80m
ILMNIllumina, Inc. 1.04%193.023.3%$357.64m
SNSSSunesis Pharmaceuticals, Inc. 3.00%3.780.7%$264.24m
BIIBBiogen, Inc. 0.93%212.581.8%$245.16m
BNTXBioNTech SE 2.24%161.030.0%$215.97m
CRSPCRISPR Therapeutics AG 10.68%70.600.6%$192.52m
BMRNBioMarin Pharmaceutical, Inc. 1.62%86.364.2%$117.47m
EXASEXACT Sciences Corp. 7.95%44.4017.7%$102.51m
NTLAIntellia Therapeutics, Inc. 16.98%63.182.2%$99.79m
AXSMAxsome Therapeutics, Inc. 1.40%41.211.8%$99.33m

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.